BioNano Genomics (BNGO) Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Posted on 4448
Bionano Genomics, Inc. (NASDAQ: BNGO)reported that Nasdaq granted the company an extra 180-day compliance period which will end on June 28th, 2021 to regain compliance with Nasdaq’s minimum USD 1.00 closing bid price per share requirement. All other requirements have been met.
Erik Holmlin, PhD, CEO of Bionano Genomics commented: “We are pleased that Nasdaq granted our request for an extension. We have been making steady progress with our business and this extension gives us extra time to regain compliance as we continue to advance the Saphyr System in our target markets of discovery research and Cytogenomics.”
The company also recently announced that Praxis Genomics, LLC received recognition from the College of American Pathologists. This makes it the first CAP-accredited CLIA certified diagnostic lab within the U.S. to offer a laboratory developed tests based on whole genome analysis with S